Intérêt des paramètres métaboliques de la TEP-TDM au 18F-FDG dans l’évaluation des patients traités par immunothérapie pour un cancer broncho-pulmonaire non à petites cellules
Year: 2022
Type: dissertation
Study design: Observational Study
Abstract: The management of patients with metastatic non-small cell lung cancer (NSCLC) treated with immunotherapy requires new predictive biomarkers for the response to treatment. The aim of this study was to assess the predictive and prognostic value of metabolic parameters measured by 18-fluorodeoxyglucose positron-emission tomography (18F-FDG PET-CT) for these patients.Material and methods: 123 patients were prospectively included and data from 119 were analyzed. The parameters were measured on examinations carried out before the start of immunotherapy, after 6-8 weeks and after 12-16 weeks. These are maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and their variation, ΔSUVmax, ΔMTV and ΔTLG. Determination of total tumor metabolic volume (MTV) was performed by manual segmentation, using an absolute fixed threshold with SUV > 4.0. Patients were followed for a minimum of 12 months. The predictive value for overall survival at 12 months and for progression-free survival at 6 months of these parameters was evaluated.Results: on the pre-treatment examination, MTV and TLG are predictive of overall survival. On post-treatment examinations, all the parameters measured, except for ΔTLG2, are predictive of overall survival and progression-free survival. More particularly, the residual metabolic tumor volume on the first post-treatment examination, called MTV1, has a strong predictive value for overall survival and progression-free survival (AUC: 0.82; CI: 0.736-0.899). By using an optimal threshold of 57cm3 determined by receiver operating characteristic (ROC) curve and by classifying patients into three groups (MTV1 = 0cm3, MTV1 ≤ 57cm3 and MTV1 > 57cm3), we obtain an efficient stratification of patients for overall and progression-free survival (6- months PFS = 100%, 78.3% and 21% respectively; 24-months OS = 100%, 67.1% and 15.9% respectively).Conclusion: residual metabolic tumor volume (MTV1) assessed on an early post-treatment 18F-FDG PET-CT examination is a strong predictive biomarker in patients treated with immunotherapy for metastatic NSCLC. It allows excellent prognostic stratification of patients. It could have an interest in selecting patients classified as progressing, with a low residual tumor volume, for whom the continuation of treatment, alone or in combination, would bring a benefit.
Source: HAL
Author: Tricarico, Pierre
Institution: Université Côte d'Azur
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Keywords: non-small cell lung cancer, immunotherapy, 18F-FDG PET/CT, metabolic tumor volume, total lesion glycolysis, SUVmax, treatment response prediction, prognostic factors, overall survival, progression-free survival, patient stratification, predictive thresholds, immune checkpoint inhibitors, PD-1 inhibitors
Open Access status: green
OpenAlex ID: W6991979003
